Please assess the completion status of the following clinical trial:

Trial Title: Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinically diagnosed perioral dermatitis associated or not associated with topical steroid use (the periorbital area may also be involved in addition to the perioral region)~* minimum severity score (PODSI) ≥ 4~* age 18 and older~Exclusion Criteria:~* Ongoing use of the following treatments is NOT allowed after the start of study drug:~Oral tetracyclines, oral erythromycin, oral steroids and oral calcineurin inhibitors. All topical treatments of the face, including steroids, calcineurin inhibitors, metronidazole, tetracyclines, erythromycin and emollients (exception: DAC Basiscreme).~* Systemic immunosuppression~* History of malignancy of any organ system, treated or untreated, within the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Pimecrolimus
- 2 (Type: PLACEBO_COMPARATOR): Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).